12 active not recruiting. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Active not recruiting 12 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 220 | 2026-08-11 | 2026-10-22 |
| Oral Intake of Mg in Controlled Asthmatic Patients Magnesium, ICS+LABA - Bronchial Asthma | Phase 2 / Phase 3 | Active not recruiting | Zagazig University | 166 | 2024-11-02 | 2025-08-14 |
| Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) - Severe Asthma | Phase 3 | Active not recruiting | AstraZeneca | 310 | 2024-09-30 | 2026-10-13 |
| Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis LP-003, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Longbio Pharma | 546 | 2024-08-01 | 2025-12-26 |
| A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) LY3650150, Placebo, Standard therapy for INCS - Perennial Allergic Rhinitis (PAR) | Phase 3 | Active not recruiting | Eli Lilly and Company | 450 | 2024-04-26 | 2026-10-27 |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations TEV-56248, Albuterol sulfate - Asthma | Phase 3 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 2769 | 2023-08-30 | 2026-11-04 |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma FF/UMEC/VI, ELLIPTA, FF/VI - Asthma | Phase 3 | Active not recruiting | GlaxoSmithKline | 138 | 2023-04-24 | 2026-11-04 |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma Benralizumab, Placebo - Asthma | Phase 3 | Active not recruiting | AstraZeneca | 94 | 2023-04-05 | 2026-10-28 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma FF/UMEC/VI - Asthma | Phase 3 | Active not recruiting | Dr. Grace Parraga | 31 | 2022-08-08 | 2025-08-29 |
| Deflazacort Vs. Prednisolone in Acute-stage ABPA Deflazacort, Prednisolone - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 150 | 2020-01-15 | 2025-02-28 |
| The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants EpiCeram - Eczema, Asthma | Phase 3 | Active not recruiting | University of Melbourne | 760 | 2018-03-06 | 2023-05-10 |
Asthma (9) · Pulmonary Eosinophilia (2) · Rhinitis, Allergic, Seasonal (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Eczema (1) · Food Hypersensitivity (1) · Rhinitis, Allergic, Perennial (1)
Hypersensitivity (12) · Hypersensitivity, Immediate (12) · Immune System Diseases (12) · Respiratory Tract Diseases (12) · Bronchial Diseases (9) · Lung Diseases (9) · Lung Diseases, Obstructive (9) · Nose Diseases (3) · Otorhinolaryngologic Diseases (3) · Rhinitis (3) · Rhinitis, Allergic (3) · Eosinophilia (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2)
Albuterol (2) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · EpiCeram (1) · Magnesium (1) · Mannitol (1) · Prednisolone (1) · Standard of Care (1) · benralizumab (1) · deflazacort (1) · tezepelumab (1)
AstraZeneca (2) · Areteia Therapeutics (1) · Dr. Grace Parraga (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Longbio Pharma (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · University of Melbourne (1) · Zagazig University (1)
United States (6) · Argentina (5) · South Korea (5) · Canada (4) · Mexico (4) · Poland (4) · Australia (3) · China (3) · Germany (3) · Israel (3) · Italy (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Bulgaria (2)
Adrian J Lowe, Doctorate (1) · Grace E Parraga, PhD (1) · Mona Bafadhel, MD (1) · Xueyan Wang (1)
2023 (2)